Patents by Inventor Leonid S. Metelitsa

Leonid S. Metelitsa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240325450
    Abstract: Embodiments of the disclosure include methods and compositions for producing NKT cells effective for immunotherapy and also methods and compositions for providing an effective amount of NKT cells to an individual in need of immunotherapy. In specific embodiments, the NKT cells are CD62L+ and have been exposed to one or more costimulatory agents to maintain CD62L expression. The NKT cells may be modified to incorporate a chimeric antigen receptor, in some cases.
    Type: Application
    Filed: June 12, 2024
    Publication date: October 3, 2024
    Applicant: Baylor College of Medicine
    Inventors: Leonid S. Metelitsa, Amy N. Courtney, Gengwen Tian
  • Publication number: 20240277764
    Abstract: The present invention regards methods and/or compositions related to Natural Killer T cells that are engineered to harbor an expression construct that encodes IL-2, IL-4, IL-7, and/or IL-15 and additionally or alternatively comprise a chimeric antigen receptor (CAR).
    Type: Application
    Filed: August 15, 2023
    Publication date: August 22, 2024
    Applicant: Baylor College of Medicine
    Inventors: Leonid S. METELITSA, Daofeng LIU, Gianpietro DOTTI, Andras HECZEY
  • Patent number: 12048716
    Abstract: Embodiments of the disclosure include methods and compositions for producing NKT cells effective for immunotherapy and also methods and compositions for providing an effective amount of NKT cells to an individual in need of immunotherapy. In specific embodiments, the NKT cells are CD62L+ and have been exposed to one or more costimulatory agents to maintain CD62L expression. The NKT cells may be modified to incorporate a chimeric antigen receptor, in some cases.
    Type: Grant
    Filed: April 21, 2016
    Date of Patent: July 30, 2024
    Assignee: Baylor College of Medicine
    Inventors: Leonid S. Metelitsa, Amy N. Courtney, Gengwen Tian
  • Publication number: 20240110154
    Abstract: The present disclosure relates to methods and compositions related to Natural Killer T cells that are engineered to harbor an expression construct that encodes an activator of the Wnt signaling pathway. Activation by expression of Wnt signaling activators or the addition of exogenous activators promotes NKT expansion over the course of multiple tumor cell challenges and improves long term tumor control in vitro. The present disclosure further includes NKT cells, populations, and methods to prepare them, that are engineered to express exogenous activators of Wnt signaling combined with chimeric antigen receptors (CARs) for therapeutic use.
    Type: Application
    Filed: February 7, 2022
    Publication date: April 4, 2024
    Applicant: Baylor College of Medicine
    Inventors: Leonid S. METELITSA, Ho NGAI
  • Publication number: 20230103554
    Abstract: TNFR2-expressing neuroblastoma cells activate monocytes via contact-dependent mTNF? signaling, leading to production of sTNF? and IL-6 by monocytes that in turn bind to TNFR1 and IL-6R on neuroblastoma cells and stimulate tumor growth via activation of NF-?B and Sta3 signaling pathways. Growing tumor recruit additional monocytes resulting in a self-promoting inflammation that fuel tumor growth. TNF inhibitors can terminate this feed-forward signal amplification loop and inhibit tumor growth. Embodiments of the disclosure include a method of using TNF inhibitors for the treatment of neuroblastoma in a subject in need thereof. Also disclosed herein is a method of a method of using TNF inhibitors for reducing tumor-promoting inflammation in an individual with cancer.
    Type: Application
    Filed: April 1, 2021
    Publication date: April 6, 2023
    Inventors: Leonid S. Metelitsa, Julie Tomolonis
  • Patent number: 11458168
    Abstract: Embodiments of the disclosure include methods and compositions for producing NKT cells effective for immunotherapy and also methods and compositions for providing an effective amount of NKT cells to an individual in need of immunotherapy. In specific embodiments, the NKT cells are CD62L+ and have been exposed to one or more costimulatory agents to maintain CD62L expression. The NKT cells may be modified to incorporate a chimeric antigen receptor, in some cases.
    Type: Grant
    Filed: May 23, 2018
    Date of Patent: October 4, 2022
    Assignee: Baylor College of Medicine
    Inventors: Leonid S. Metelitsa, Amy N. Courtney, Gengwen Tian
  • Patent number: 11266689
    Abstract: Embodiments of the disclosure include methods and compositions for producing NKT cells effective for immunotherapy and also methods and compositions for providing an effective amount of NKT cells to an individual in need of immunotherapy. In specific embodiments, the NKT cells are CD62L+ and have been exposed to one or more costimulatory agents to maintain CD62L expression. The NKT cells may be modified to incorporate a chimeric antigen receptor, in some cases.
    Type: Grant
    Filed: June 3, 2019
    Date of Patent: March 8, 2022
    Assignee: Baylor College of Medicine
    Inventors: Leonid S. Metelitsa, Amy N. Courtney, Gengwen Tian
  • Publication number: 20210252056
    Abstract: Embodiments of the disclosure encompass methods and compositions related to cancer treatment with particular immune effector cells as adoptive immunotherapy and/or with soluble proteins to which the immune effector cells are able to bind. In some cases, the soluble proteins are molecular adaptors that allow targeting of cancer cells that lack expression of a tumor antigen to which the adoptive immunotherapy is directed. In some embodiments, the soluble proteins are exogenously provided as cytokine-cytokine receptor pairs that improve adoptive immunotherapy.
    Type: Application
    Filed: April 24, 2019
    Publication date: August 19, 2021
    Inventors: Leonid S. Metelitsa, Bin Liu, Daofeng Liu, Jingling Jin
  • Publication number: 20210220403
    Abstract: The present invention regards methods and/or compositions related to Natural Killer T cells that are engineered to harbor an expression construct that encodes IL-2, IL-4, IL-7, and/or IL-15 and additionally or alternatively comprise a chimeric antigen receptor (CAR). In specific embodiments, the CAR is a CAR that targets the GD2 antigen, for example in neuroblastoma.
    Type: Application
    Filed: October 15, 2020
    Publication date: July 22, 2021
    Applicant: Baylor College of Medicine
    Inventors: Leonid S. METELITSA, Daofeng Liu, Gianpietro Dotti, Andras Heczey
  • Publication number: 20210106622
    Abstract: The present invention regards methods and/or compositions related to Natural Killer T cells that are engineered to harbor an expression construct that encodes IL-2, IL-4, IL-7, and/or IL-15 and additionally or alternatively comprise a chimeric antigen receptor (CAR). In specific embodiments, the CAR is a CAR that targets the GD2 antigen, for example in neuroblastoma.
    Type: Application
    Filed: October 15, 2020
    Publication date: April 15, 2021
    Applicant: Baylor College of Medicine
    Inventors: Leonid S. METELITSA, Daofeng Liu, Gianpietro Dotti, Andras Heczey
  • Publication number: 20200216810
    Abstract: An isolated human NKT cell or a plurality of cells thereof, having reduced or no detectable expression of endogenous beta-2-microglobulin (B2M); endogenous MHC class II-associated invariant chain (Ii); or both. Methods to generate the cell or cells, and methods of treatment using the cell or cells are also provided.
    Type: Application
    Filed: August 10, 2018
    Publication date: July 9, 2020
    Applicant: Baylor College of Medicine
    Inventors: Leonid S. Metelitsa, Jingling Jin, Bin Liu
  • Publication number: 20200163992
    Abstract: Embodiments of the disclosure include methods and compositions for producing NKT cells effective for immunotherapy and also methods and compositions for providing an effective amount of NKT cells to an individual in need of immunotherapy. In specific embodiments, the NKT cells are CD62L+ and have been exposed to one or more costimulatory agents to maintain CD62L expression. The NKT cells may be modified to incorporate a chimeric antigen receptor, in some cases.
    Type: Application
    Filed: June 3, 2019
    Publication date: May 28, 2020
    Inventors: Leonid S. Metelitsa, Amy N. Courtney, Gengwen Tian
  • Publication number: 20180264040
    Abstract: Embodiments of the disclosure include methods and compositions for producing NKT cells effective for immunotherapy and also methods and compositions for providing an effective amount of NKT cells to an individual in need of immunotherapy. In specific embodiments, the NKT cells are CD62L+ and have been exposed to one or more costimulatory agents to maintain CD62L expression. The NKT cells may be modified to incorporate a chimeric antigen receptor, in some cases.
    Type: Application
    Filed: May 23, 2018
    Publication date: September 20, 2018
    Inventors: Leonid S. Metelitsa, Amy N. Courtney, Gengwen Tian
  • Publication number: 20170281683
    Abstract: Embodiments of the disclosure include methods and compositions related to immunotherapy that targets glypican-3. In particular embodiments, immune cells engineered to comprise a chimeric antigen receptor that targets glypican-3 are contemplated, and uses thereof. In particular embodiments, medical conditions that are associated with glypican-3 expression or an overexpression of glypican-3 are treated with GPC3 CARs.
    Type: Application
    Filed: September 25, 2015
    Publication date: October 5, 2017
    Inventors: Andras Heczey, Stephen M. G. Gottschalk, Leonid S. Metelitsa, Gianpietro Dotti, Wenpeng Li
  • Publication number: 20160310532
    Abstract: Embodiments of the disclosure include methods and compositions for producing NKT cells effective for immunotherapy and also methods and compositions for providing an effective amount of NKT cells to an individual in need of immunotherapy. In specific embodiments, the NKT cells are CD62L+ and have been exposed to one or more costimulatory agents to maintain CD62L expression. The NKT cells may be modified to incorporate a chimeric antigen receptor, in some cases.
    Type: Application
    Filed: April 21, 2016
    Publication date: October 27, 2016
    Inventors: Leonid S. Metelitsa, Amy N. Courtney, Gengwen Tian
  • Publication number: 20140255363
    Abstract: The present invention regards methods and/or compositions related to Natural Killer T cells that are engineered to harbor an expression construct that encodes IL-2, IL-4, IL-7, and/or IL-15 and additionally or alternatively comprise a chimeric antigen receptor (CAR). In specific embodiments, the CAR is a CAR that targets the GD2 antigen, for example in neuroblastoma.
    Type: Application
    Filed: September 14, 2012
    Publication date: September 11, 2014
    Applicant: BAYLOR COLLEGE OF MEDICINE
    Inventors: Leonid S. Metelitsa, Daofeng Liu, Gianpietro Dotti, Andras Heczey